⌘K
Loading ticker…
As of 2026-08-24, Acurx Pharmaceuticals, Inc. Common Stock (ACXP) has a 3-month relative strength percentile of 15 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 35. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 8.5%, relative volume 0.67×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
ACXP is in a stage 4 downtrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -6.7% / -45.4%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
ACXP appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $115K notional.
Held by 1 ETFs · $115K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $115K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ACXP Jan avg: -9.86% median: -9.90% win: 0% σ: 3.93% n: 4 2022-04-12 → 2026-07-31 | ACXP Feb avg: -14.94% median: -10.14% win: 0% σ: 14.92% n: 4 2022-04-12 → 2026-07-31 | ACXP Mar avg: 23.05% median: -5.05% win: 50% σ: 85.33% n: 4 2022-04-12 → 2026-07-31 | ACXP Apr avg: -10.57% median: -10.20% win: 40% σ: 19.92% n: 5 2022-04-12 → 2026-07-31 | ACXP May avg: -5.62% median: -8.33% win: 40% σ: 15.76% n: 5 2022-04-12 → 2026-07-31 | ACXP Jun avg: 5.15% median: -10.36% win: 40% σ: 28.80% n: 5 2022-04-12 → 2026-07-31 | ACXP Jul avg: -15.24% median: -7.10% win: 0% σ: 14.07% n: 5 2022-04-12 → 2026-07-31 | ACXP Aug avg: -8.68% median: -3.72% win: 25% σ: 13.92% n: 4 2022-04-12 → 2026-07-31 (current) | ACXP Sep avg: -14.27% median: -13.84% win: 0% σ: 6.20% n: 4 2022-04-12 → 2026-07-31 | ACXP Oct avg: 68.82% median: 9.84% win: 75% σ: 125.47% n: 4 2022-04-12 → 2026-07-31 | ACXP Nov avg: -21.71% median: -28.11% win: 25% σ: 17.66% n: 4 2022-04-12 → 2026-07-31 | ACXP Dec avg: -9.28% median: -13.04% win: 50% σ: 30.80% n: 4 2022-04-12 → 2026-07-31 |